Apogee Technology Presents Data On Intradermal Immunization

Apogee Technology has announced the publication of an article on its intradermal immunization approach in the Online Early Edition of PNAS (the Proceedings of the National Academy of Sciences of the USA).

An article entitled ‘Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization’ describes important findings on the in vivo and in vitro performance of company’s microneedle technology and demonstrates effective intradermal vaccination from an adjuvanted patch delivery system.

The technology, when used as part of an intradermal delivery system for hepatitis B surface antigen, demonstrated superior activity in the appropriate animal model compared to conventional intramascular administration. It also provided significant dose sparing potential – the property, which can be highly desirable during times of vaccine shortages, such as epidemic emergencies, and for reducing the cost of vaccine manufacturing.

Alexander Andrianov, vice president of research & development at Apogee and corresponding co-author of the paper, said: “We are honored to have this research published in the PNAS as it serves as an important validation of Apogee’s approach to intradermal vaccination.

“Intradermal immunization using microneedles has not been fully compatible with many vaccine adjuvants including alum, the most common adjuvant used in the vaccine market globally. We believe that introduction of polyphosphazene immunoadjuvant of the present study as a biologically potent and synergistic constituent of microneedle-based intradermal vaccine delivery represents an important step forward in the advancement of our technology.”